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ABSTRACT
HYDROXYCHLOROQUINE PREVENTS ANTIPHOSPHOLIPID ANTIBODYINDUCED INHIBITION OF TROPHOBLAST MIGRATION
Women with antiphospholipid syndrome (APS) are at high risk of recurrent pregnancy
complications. Antiphospholipid antibodies (aPL) target the trophoblast by binding beta2glycoprotein I (β2GPI) and alter human first trimester trophoblast function by: triggering
a pro-inflammatory cytokine response; modulating angiogenic factor secretion; and
inhibiting cell migration. While patients with APS are often treated with
hydroxychloroquine (HCQ), and it is safe to use during pregnancy, little is known about
the effects of HCQ on aPL-associated adverse pregnancy outcomes. Therefore, the
objective of this study was to test the hypothesis that HCQ prevents the effects of aPL on
human first trimester trophoblast function. A human first trimester trophoblast cell line
was treated with or without anti-human β2GPI monoclonal antibodies in the presence or
absence of HCQ. Using ELISA, culture supernatants were analyzed for: proinflammatory cytokines IL-8 and IL-1β; pro-angiogenic factors VEGF and PlGF; antiangiogenic factors sFlt-1 and soluble Endoglin; pro-migratory cytokine IL-6; and tissue
inhibitors of metalloproteinase 1 and 2 (TIMP1 and TIMP2). Cell migration was
measured using a colormetric two-chamber assay. The aPL-induced upregulation of
trophoblast IL-8, IL-1β, PlGF, and sEndoglin secretion was not significantly altered by
the presence of HCQ. The presence of HCQ partially, yet significantly, reversed the aPLinduced inhibition of trophoblast cell migration and secretion of pro-migratory cytokine
IL-6. aPL-induced upregulation of trophoblast TIMP secretion appears to inhibit cell
migration. HCQ was unable to completely prevent aPL-induced TIMP secretion, and this
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may explain why migration was only partially restored. HCQ reversed the aPL-induced
inhibition of IL-6 secretion and partially limited the ability of aPL to reduce trophoblast
cell migration. Our data indicate the possibility that some form of combination therapy
that includes HCQ may be beneficial to pregnant APS patients and warrants further
investigation.

Published in American Journal of Reproductive Immunology:
Albert, C.R., Schlesinger, W.J., Viall, C.A., Mulla, M.J., Brosens, J.J., Chamley, L.W.,
and Abrahams, V.M. 2014. Effect of hydroxychloroquine on antiphospholipid antibodyinduced changes in first trimester trophoblast function. Am J Reprod Immunol 71:154164.
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INTRODUCTION

Classification of Antiphospholipid Syndrome
Antiphospholipid syndrome (APS), an autoimmune systemic disease characterized by
circulating antiphospholipid antibodies (aPL), places women at risk of adverse pregnancy
outcomes, such as recurrent pregnancy loss and late gestational complications including
preeclampsia and associated premature delivery, HELLP syndrome (hemolytic anemia,
elevated liver enzymes, and low platelet counts), and intrauterine growth restriction (1).
Complications such as preeclampsia are also known to increase health risks for the
mother later in life, including hypertension and cardiovascular disease (2). While health
consequences for the neonate are known to be related to low birth weight and
prematurity, several studies have suggested potential negative long-term cognitive and
psychological outcomes, including autism spectrum and other neurodevelopmental
disorders (3, 4).

Methods of treatment for APS during pregnancy typically involve low molecular weight
heparin (LMWH), either alone or in combination with aspirin (5, 6). In some studies, this
treatment has been shown to significantly increase the live birth rate in APS patients who
have experienced multiple miscarriages. However, the incidence of severe late obstetric
complications, including preeclampsia, intrauterine growth restriction and prematurity,
remains high (5, 6). In addition, clinical and experimental studies have produced
contradictory results regarding the effectiveness of heparin in preventing adverse
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pregnancy outcomes in APS (7-10). Therefore, the development of improved strategies
for the prevention of pregnancy complications in APS is a pressing concern.

APS was recognized as a unique form of autoantibody-induced thrombophilia in the early
1980s (11). The true frequency of APS is unknown, but it is estimated that the incidence
is around 5 new cases per 100,000 persons per year, and the prevalence is around 40-50
cases per 100,000 persons (12). The male-to-female ratio is about 1:3.5, and the mean age
of onset is 35 years (13). APS is specifically characterized by recurrent thrombosis and
pregnancy complications. Other manifestations include cardiac valvular disease renal
thrombotic microangiopathy, thrombocytopenia, hemolytic anemia, and cognitive
impairment (11). In fact, APS is the most common cause of acquired thrombophilia in the
general population. Up to twenty percent of patients who have had a stroke at less than
fifty years of age have been found to have circulating aPL (11). APS may occur as a
primary disease, or may occur as secondary to another autoimmune disease, including
systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjogren’s syndrome, and
certain malignancies (14, 15). In fact, forty percent of patients diagnosed with SLE with
have circulating aPL (11).

Diagnosis of APS must involve at least one clinical criterion and one laboratory criterion.
Clinical criteria involve either vascular thrombosis or obstetric morbidity. Vascular
thrombosis must be confirmed by Doppler study, imaging, or histopathology. Obstetric
morbidity must include at least one unexplained fetal demise beyond ten weeks of
gestation (with a morphologically normal fetus), at least one premature birth due to
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eclampsia/preeclampsia/placental insufficiency, or at least three unexplained consecutive
and spontaneous miscarriages before ten weeks gestation (11, 15, 16).

Laboratory

criteria include the presence of anticardiolipin antibodies, anti-beta2-glycoprotein I
antibodies, or lupus anticoagulant (15).

Pathogenesis of Systemic and Obstetric Antiphospholipid Syndrome
The pathogenesis of APS involves acquired antibodies (aPL), which are IgG, IgM, or IgA
subtypes that react against negatively charged phospholipids. Such antibodies include, as
discussed above, anticardiolipin antibodies, anti-beta2-glycoprotein I antibodies, and
lupus anticoagulant (14). The main autoantigen for APS is beta2-glycoprotein I (β2GPI), a
protein localized to the plasma membrane that mediates aPL binding to target cells such
as platelets, monocytes, endothelial cells, and trophoblasts (14). These antibodies
increase thrombus formation in both the arterial and venous circulation. Prothrombotic
effects of aPL involve inhibition of the fibrinolytic system and activation of the
coagulation cascade, activation of the complement system, and inhibition of annexin A5,
a potent anticoagulant protein on endothelial cell surfaces (14).

Despite the association of APS with thrombosis and the success of anticoagulants such as
heparin in preventing pregnancy loss, recent studies have shown that intravascular or
intravillous blood clots are not typically found in placental samples from APS patients
(17). Rather, clinical and experimental studies suggest that the primary causes for adverse
pregnancy events are inflammatory processes, including cytokine production,
complement deposition, and immune cell activation (18-22). Furthermore, studies
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indicate that there is placental dysfunction and insufficient placentation in APScomplicated pregnancies (17, 23, 24). Placental dysfunction in APS appears to be related
to reduced migration of trophoblast cells and trophoblast invasion, as well as limited
uterine spiral artery transformation (17, 23, 24).

Antiphospholipid antibodies are able to specifically target the placenta by binding β2GPI
(25-27). β2GPI is a phospholipid-binding protein that binds with high affinity to the
negatively charged phospholipids on the inner cell membrane. Typically, cells only bind
β2GPI under pathologic and apoptotic conditions, as this is the only time that the
negatively charged inner phospholipids will be exposed to the outer membrane. However,
the trophoblast is unique because it constitutively expresses β2GPI on its cell surface
under normal circumstances, due to the high levels of proliferation and differentiation
(25, 28). In addition, the trophoblast synthesizes β2GPI itself, increasing the levels of cell
surface expressed and circulating β2GPI in the local environment. β2GPI has been shown
to be expressed on the surface of extravillous trophoblast cells that invade the decidua of
the uterus, as well as on the syncytiotrophoblast cells (28). The placenta is, therefore, a
major target for circulating aPL, which recognize β2GPI.

Physiology of Placentation
Normal placentation occurs at six or seven days after conception, with the adhesion of the
blastocyst to the uterine wall and the trophoectoderm giving rise to the placental
trophoblast cells. The trophoblast layer of the placenta consists of an inner
cytotrophoblast, which contains the stem cells that proliferate and differentiate. The
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second layer is the syncytiotrophoblast, which is formed from the differentiation and
fusion of cytotrophoblast cells. The cytotrophoblast cells invade the decidua, the
proliferative layer of the uterus present during pregnancy. Cytotrophoblasts eventually
differentiate into extravillous trophoblast cells, which migrate from the trophoblast layer
to invade the entire endometrium and the inner third of the myometrium (28, 29). These
cells remodel the maternal spiral arteries, resulting in increased blood flow to the
placenta.

The innate invasiveness of cytotrophoblasts is driven by both autocrine and paracrine
signals. Signals like interleukin-6 (IL-6) produced by the trophoblast can drive migration
through activation of the STAT3 pathway (24, 30, 31). Similarly, factors produced by the
decidua, such as leukemia inhibitory factor (LIF) and IL-11, can also promote trophoblast
invasiveness (31, 32). Trophoblast invasiveness is also related to the secretion and
balance of proteinases such as matrix metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinases (TIMPs) (29). MMPs, a family of zinc-dependent endopeptidases,
function by degrading and remodeling components of the extracellular matrix. Several
human MMPs have been identified, including collagenases, gelatinases, and membraneassociated MMPs (33). TIMPs belong to a family of endogenous extracellular proteins
that function as MMP inhibitors by directly binding MMPs or by activating nuclear
transcription factors that control the expression of MMPs (33). Several studies have
indicated that the levels of MMP2, MMP9, TIMP1, and TIMP2 are particularly important
for trophoblast invasion (34, 35). Abnormally low levels of MMP2 and MMP9 and
abnormally high levels of TIMP1 and TIMP2 have been implicated in adverse pregnancy
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outcomes such as preeclampsia and maternal hypertension (33, 34). The normal invasion
of the decidua and remodeling of the maternal vasculature are impaired in disease states
such as preeclampsia, preterm birth, and miscarriage (36). In these cases, there is
inadequate remodeling of the maternal vasculature, shallow invasion of the decidua by
trophoblast cells, and increased inflammation at the maternal-fetal interface (23, 28).

Effects of Antiphospholipid Antibodies on the Trophoblast
Many studies have investigated the potential mechanisms by which aPL affect
trophoblast function by examining placental specimens from patients with APS or using
murine models of APS in pregnancy (19, 21, 22). These studies have noted the existence
of necrosis and acute and chronic inflammation in placental tissue from APS patients
(22). In addition, they have implicated aPL-induced upregulation of complement C5
levels, neutrophil response, and tissue factor production as mediators of fetal injury in
APS, leading to increased inflammation in the decidua and to subsequent miscarriages
(19, 21). Many in vitro studies have examined the effects of aPL on term trophoblast
cells. The presence of aPL has been shown to be associated with overall decreased
viability of term trophoblast cells, with decreased trophoblast proliferation and increased
trophoblast cell death (37). In addition, studies have noted that term trophoblast cells
exposed to aPL demonstrate decreased syncytialization and decreased giant cell
formation (38-40). Term trophoblast cells exposed to aPL have also been shown to
produce reduced levels of syncytiotrophoblast hormones such as hCG (37, 41, 42).
Several studies have shown the presence of aPL is associated with decreased term
trophoblast cell invasion, although it should be noted that term trophoblast cells have
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decreased invasive capacity than earlier gestational trophoblast cells (38, 43). Finally,
term trophoblast cells exposed to aPL have been shown to have increased levels of
prothrombotic thromboxane and decreased levels of antithrombotic annexin V (44, 45).

Such studies are helpful in elucidating the effects of aPL in the late gestational and term
trophoblast. However, aPL are always present in patients and are therefore present at the
time of implantation and early in pregnancy. Moreover, obstetric APS includes placental
insufficiency and preeclampsia, which are thought to be established early in pregnancy
due to impaired early placental implantation and differentiation. Therefore, an
investigation of the effects of aPL on first trimester trophoblast cells is critical. Indeed,
studies from the laboratory have begun to examine the effects of aPL on human first
trimester trophoblast function and some of the mechanisms involved (20, 24, 46). aPL
trigger human first trimester trophoblast cells to produce elevated levels of proinflammatory cytokines and chemokines, such as IL-8, IL-1β, through activation of the
innate immune receptor, Toll-like receptor 4 (TLR4) (20). aPL have also been shown to
alter first trimester trophoblast function by inhibiting trophoblast migration (24). This
inhibition of migration has been linked to an aPL-induced downregulation of IL-6, a
cytokine that normally promotes cell migration through the phosphorylation and
activation of STAT3 (31). Indeed, aPL have been shown to decrease levels of both IL-6
and phosphorylated STAT3 (24). In addition, aPL have been shown to modulate the
trophoblast angiogenic factor profile by increasing pro-angiogenic vascular endothelial
growth factor (VEGF) and placenta growth factor (PlGF), as well as increasing antiangiogenic soluble Endoglin (sEndoglin) secretion (46). Finally, aPL have been
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implicated in the modulation of MMPs and TIMPs. Specifically, aPL have been shown to
be associated with downregulation of MMP-2 and MMP-9 in primary cultures obtained
from first trimester placental samples, in a first trimester trophoblast cell line, and in a
human choriocarcinoma cell line (47, 48). An additional study has shown that aPL
downregulate MMP-2 and MMP-9 in term trophoblast cells (43).

The identification of therapeutic interventions that can prevent such trophoblast responses
to aPL may translate clinically to improved pregnancy outcomes in APS patients. Indeed,
this in vitro model has been used to assess the potential impact of heparin, aspirin,
aspirin-triggered lipoxin, and pravastatin on trophoblast responses to aPL (9, 20, 24, 46,
49, 50). These studies have reported that LMWH may have some benefits, specifically in
terms of partially reversing the upregulation of pro-inflammatory cytokines IL-8 and IL1β (9). LMWH has also been shown to have some benefit in reversing the
downregulation of MMP-2 (51). However, LMWH has also been shown to increase
levels of anti-angiogenic factor soluble fms-like tyrosine kinase-1 (sFlt-1) (46). This
could potentially have an adverse effect on pregnancy, as increased levels of sFlt-1 have
been associated with preeclampsia, and overexpression of sFlt-1 in mice leads to
preeclampsia-like symptoms (52-54). Aspirin-triggered lipoxin has been shown to have
some benefit in restoring IL-6 levels and cell migration (50). Due to these limited
benefits, there is a need to evaluate the efficacy of alternative therapeutics, especially
those that may help reverse the aPL-induced modulation of trophoblast angiogenic factor
secretion and impaired trophoblast migration.
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Mechanism of Action of Hydroxychloroquine
Patients with SLE and APS are often treated with the anti-malarial drug
hydroxychloroquine (HCQ), which has been shown to be beneficial in their management
(55, 56). Quinines were first recognized as anti-malarial agents over hundreds of years
ago, with their first use traditionally attributed to Incan descendants in Peru in 1630, who
used a bark powder to treat a febrile illness (57). During World War II, the widespread
use of quinines as malarial prophylaxis for soldiers led to the discovery that soldiers’
rashes and inflammatory arthritis improved as well, leading to the first trial showing
antimalarials were effective in the treatment of SLE (57). In more recent times, such
antimalarials have become established agents for treating rheumatic diseases such as
SLE, Sjogren’s syndrome, chronic Q fever, and skin diseases (55).

In addition to having anti-thrombotic effects, HCQ has anti-inflammatory and
immunomodulatory properties, which recent studies have sought to characterize (55, 56,
58, 59). Chloroquines are lipophilic, and thus cross cell membranes readily (56). As weak
bases, chloroquines accumulate in lysosomes, increase the pH of the intracellular
compartment, and impair the function of phagocytosis that normally requires lysosomal
acidification for protease functioning. (60). In addition, chloroquines have been shown to
decrease the production of inflammatory cytokines, including IL-1, IL-2, IL-6, IL-17, IL22, interferon-alpha and gamma, and tumor necrosis factor-alpha (57, 61, 62). HCQ is
also proposed to inhibit the effects of prostaglandins by inhibiting phospholipase A2 (57).
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More recently, HCQ has been shown to affect TLR signaling (56). Specifically,
antimalarials such as HCQ are thought to inhibit the activation of intracellular TLRs,
such as TLR3, TLR7, TLR8 and TLR9 (59, 63). Such TLRs normally bind nucleic acids
(bacterial and viral) into late endosomes and early lysosomes, but are also known to bind
endogenous genetic material, which perhaps evolved as a response to damaged tissue (62,
63). Such TLRs are implicated in the pathogenesis of autoimmune diseases such as APS
and lupus, due to the presence of antibodies directed at nucleic material. Chloroquines,
which target microsomes and disrupt the acidic pH as described above, are therefore
postulated to block such TLR interaction with nucleic acids (59). However, an alternative
pathway has also been proposed, in which chloroquines inhibit TLR activation by
directly binding to nucleic acids and masking their TLR-binding epitope, rather than
functioning by inhibiting endosomal proteolysis as previously thought (58). A further
proposed mechanism suggests that HCQ may function by preventing the phosphorylation
and activation of mitogen-activated protein kinases, thus preventing the downstream
effects of lipopolysaccharide-induced inflammatory response via TLR4 (64). Studies
from our group have demonstrated that aPL induce trophoblast inflammation via TLR4
(20). Moreover, recent evidence suggests that trophoblast fusion and differentiation are
inhibited by aPL via a TLR4-mediated pathway, and that HCQ is able to reverse this
effect (40).

Safety of Hydroxychloroquine
HCQ is known to be a very safe medication when taken at therapeutic doses, but toxicity
is recognized at doses above the safety margin (65). Toxic manifestations include
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cardiovascular events such as hypotension, decreased myocardial function, cardiac
arrhythmias, and cardiac arrest (57, 65). It is also known to have CNS toxicity, causing
confusion, convulsions, and coma. At typical oral doses used for rheumatic disease, the
main side effects of chloroquines are nausea, headache, and pruritus. Irreversible
retinopathy and ototoxicity are possible at high daily doses, typically above 250 mg per
day (66). Currently, the American Academy of Ophthalmology recommends a baseline
screening ophthalmologic exam to all patients beginning hydroxychloroquine, followed
by annual screening after five years of medication use (62).

HCQ is known to cross the placenta, with fetal levels shown to be equivalent to maternal
levels (67). However, HCQ is considered safe to use during pregnancy, with no evidence
of fetal toxicity or congenital abnormalities (62, 67-70). Studies have specifically
examined the association of HCQ exposure in utero with fetal ocular toxicity and found
no evidence (71). However, little is known about the effects of HCQ on aPL-induced
adverse pregnancy outcomes. Recent studies have reported that HCQ reduces the binding
of aPL-β2GPI complexes to phospholipid bilayers and protects the anticoagulant protein
annexin A5 from disruption by aPL in the term trophoblast, again by reduced antibody
binding (72-74). Such studies suggest that HCQ might be able to prevent many of the
effects of aPL on the trophoblast cell that are downstream effects of aPL binding to
β2GPI.

Since circulating aPL are present in women with APS at the time of implantation, the
objective of this study was to investigate the impact that HCQ has on human first
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trimester trophoblast cell responses to aPL. The ultimate goal of this study was to
determine whether HCQ could be used as a therapy to prevent adverse pregnancy
outcomes in women with APS. The specific hypotheses of this project were:
1. HCQ can prevent the TLR4-mediated pro-inflammatory cytokine response triggered
by aPL
2. HCQ can prevent the aPL-induced modulation of pro- and anti-angiogenic factor
secretion
3. HCQ can prevent the aPL-induced inhibition of IL-6 production and cell migration
4. aPL modulate the expression of MMPs and TIMPs, and this can be reversed by HCQ

METHODS

Trophoblast Cell Line
The human first trimester trophoblast cell line, SVneo transformed HTR8, was used in all
experiments. The cell line (HTR8) was a gift from Dr. Charles Graham (Queen's
University, Kingston, ON, Canada). This cell line was established from explant cultures
of first trimester (7 weeks of gestation) chorionic villi. The cells were immortalized
through transfection with cDNA encoding the simian virus-40 large T antigen (75). This
cell line has been well characterized and shown to express various cell markers
characteristic of extravillous invasive trophoblast cells (76). As extravillous trophoblast
cells are responsible for invasion of the decidua and transformation of the spiral arteries,
this cell line is an excellent in vitro model for studies of mechanisms regulating the
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human first trimester trophoblast growth, migration, and invasion that is associated with
normal placentation.

HTR8 cells were grown in sterile 75 cm2 polystyrene cell culture flasks at 37°C/5% CO2.
The culture media used was RPMI-1640 (Gibco; Grand Island, NY), supplemented with
10% fetal bovine serum (Hyclone; South Logan, UT), 10 mM Hepes, 0.1 mM MEM nonessential amino acids, 1 mM sodium pyruvate, and 100 nm penicillin/streptomycin
(Gibco). The cells were grown until confluent, at which point they were split and plated
for experiments or maintained in continued culture.

The cells were split through the use of 3-5 mL of 0.05% Trypsin followed by activation
with a brief incubation at 37°C until the cells had detached. An equal volume of culture
media was added to inactivate the trypsin and the solution was transferred to a sterile 10
mL polypropylene tube and centrifuged at room temperature at 3000 rpm for 10 minutes.
The pellet was resuspended in growth media and the cells were counted and either plated
for future experimentation or seeded into T75 for further propagation.

Antiphospholipid Antibodies
The aPL used in all experiments were the mouse IgG1 anti-human β2GPI mAbs, ID2 and
IIC5. These antibodies were produced by Larry W. Chamley (Department of Obstetrics
and Gynecology, University of Auckland, New Zealand), and have been previously
characterized (77). ID2 and IIC5 bind β2GPI in the same manner as human aPL when
immobilized on a suitable negatively charged surface, such as the phospholipids,
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cardiolipin or phosphatidyl serine, or irradiated polystyrene (78). ID2 and IIC5 have been
shown to alter trophoblast function similarly to patient-derived polyclonal aPL upon
binding to first trimester trophoblast cells (20, 46).

Cell Viability Assay
Trophoblast cell viability was determined using the CellTiter 96 viability assay
(Promega, Madison, WI), as previously described (79). Cells (1x104) were seeded into
wells of a 96-well plate in growth media and incubated overnight. The media was then
replaced with serum-free OptiMEM (Invitrogen; Carlsbad, CA), and cells were incubated
for another 4 hours. Cells were then treated with HCQ (Sigma Aldrich) at concentrations
of 0, 0.01, 0.1, 1, 10 and 100 µg/ml. HCQ was reconstituted in endotoxin-free water and
subsequent dilutions made using OptiMEM prior to treatment. After 48 hours, the
CellTiter 96 substrate (Promega) was added to all wells and incubated for 2 hours at
37°C. Optical densities were read at 490 nm. All samples were assayed in triplicate, and
cell viability was presented as a percentage of the untreated control (0µg/ml).

Cytokine, Angiogenic Factor, and TIMP Secretion
Trophoblast cells (1x105) were seeded into 35 mm tissue culture dishes in growth media
and allowed to adhere overnight. After cells were 70% confluent, the growth media was
replaced with serum-free OptiMEM (Invitrogen) and cells incubated for another 4 hours.
Cells were then treated with or without aPL (ID2 or IIC5) at 20µg/ml in OptiMEM
(Invitrogen) in the presence and absence of HCQ at 1µg/ml. After 72 hours, cell-free
supernatants were collected by centrifugation at 400g for 10 minutes and stored at -80˚C
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until analysis was performed. At the time of analysis, the supernatants were thawed on
ice. The concentrations of interleukin 8 (IL-8), interleukin 1β (IL-1β), interleukin 6 (IL6), vascular endothelial growth factor (VEGF), placenta growth factor (PlGF), soluble
fms-like tyrosine kinase-1 (sFlt-1), soluble Endoglin (sEndoglin), tissue inhibitor of
metalloproteinase 1 (TIMP1) and tissue inhibitor of metalloproteinase 2 (TIMP2) were
measured by ELISA (R & D Systems; Minneapolis, MN).

Cell Migration
To assess trophoblast migration, a two chamber colorimetric assay was used, as
previously described (24). An 8µm pore size cell culture insert served as the top chamber
(BD Biosciences, Franklin Lakes, NJ, USA), while the lower chambers were wells of a
24-well tissue culture plate (BD Falcon, Franklin Lakes, NJ, USA). The lower chamber
was filled with 800µL of OptiMEM while the top chamber was seeded with 1 x 105 cells
HTR8 cells suspended in 200µL of treatments. Following a 48-hour incubation, the 8µm
inserts were removed and trophoblast migration across the membrane was determined
using the QCM 24-Well Colorimetric Cell Migration assay according to the
manufacturer’s instructions (Chemicon International, Temecula, CA). Brieﬂy, migrated
cells were stained, collected, and lysed. The resulting colored mixture was transferred to
a 96-well plate and optical densities read in triplicate at 560 nm. A 100% migration
control consisted of the starting number of cells (1 x 105). Observed optical density
values were measured using a BioRad plate reader (Hercules, CA, USA), and were
expressed as a percentage of the starting total number of cells.

	
  

21

Statistical Analysis
All experiments were performed at least three times. Data from individual experiments
were pooled and expressed as mean ± standard error of the mean (SEM). Statistical
signiﬁcance was set at p<0.05 and was determined by one-way ANOVA using Prism
software (GraphPad Software, Inc., La Jolla, CA).

I produced the data for the all of the cell viability studies, cytokine and angiogenic factor
studies, and migration studies, with the exception of the data for the TIMP1 and TIMP2
studies, which were produced by Mr. Schlesinger. With the help of Dr. Abrahams, I
performed the statistical analysis.

RESULTS

HCQ decreases trophoblast viability at high doses
The first objective of this study was to determine the concentration range of HCQ that
has no trophoblast cytotoxicity. Figure 1 shows that the two highest HCQ doses tested,
10µg/ml and 100µg/ml, significantly reduced trophoblast cell viability when compared to
the untreated control (0µg/ml). At all others concentrations tested, there was no
significant effect on cell viability (Figure 1). Therefore, for all subsequent experiments,
the highest non-cytotoxic dose of 1µg/ml HCQ was used, which is consistent with
previous reports studying the effects of HCQ on the trophoblast (72-74).
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Figure 1: High levels of HCQ reduce trophoblast cell viability. The first trimester trophoblast cell line
(HTR8) was incubated with no treatment (0µg/ml) or HCQ at 0.01, 0.1, 1, 10 or 100µg/ml for 72hrs. Chart
shows cell viability as a percentage of the 0µg/ml HCQ control. Data are from three independent
experiments. *p<0.0001 relative to the control.

HCQ has no effect on aPL-induced trophoblast secretion of pro-inflammatory cytokines
or chemokines
Having established the HCQ dose, we first sought to determine the effect of HCQ on
aPL-induced trophoblast inflammation (9, 20, 49). Treatment of trophoblast cells with
ID2 or IIC5 induced a significant increase in the secretion of IL-8 when compared to the
no treatment (NT) control. The presence of HCQ had no significant effect on aPLinduced trophoblast IL-8 production (Figure 2A). Similarly, treatment of trophoblast cells
with ID2 induced a significant increase in secretion of IL-1β and this was unaffected by
the presence of HCQ (Figure 2B). HCQ alone had no effect on basal trophoblast IL-8 or
IL-1β secretion (Figure 2).
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Figure 2: HCQ has no effect on aPL-induced trophoblast secretion of pro-inflammatory cytokines. HTR8
cells were incubated with either no treatment (NT) or the anti-β2GPI mAbs, ID2 or IIC5 (20µg/ml), in the
presence of media or HCQ (1µg/ml) for 72hrs. Supernatants were assayed for (A) IL-8 and (B) IL-1β. Data
are from nine independent experiments. *p<0.05; **p<0.001 relative to the NT control.

HCQ has no effect on aPL-induced modulation of trophoblast angiogenic factor
production
We next investigated the effect of HCQ on aPL-induced modulation of trophoblast
angiogenic factor secretion (9, 46, 49). HCQ alone had no effect on basal trophoblast
secretion of VEGF (Figure 3A), PlGF (Figure 3B), sEndoglin (Figure 3C), or sFlt-1
(Figure 3D). Treatment of trophoblast cells with ID2 or IIC5 induced a significant
increase in the secretion of VEGF (Figure 3A). The presence of HCQ significantly
lowered the ID2-induced VEGF secretion, but had no effect on IIC5-induced VEGF
(Figure 3A). Treatment of trophoblast cells with ID2 or IIC5 significantly increased
trophoblast secretion of PlGF, and this was unaffected by HCQ (Figure 3B). Neither ID2
nor IIC5 in the presence or absence of HCQ had any effect on trophoblast sFlt-1 secretion
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(Figure 3C). ID2 significantly increased trophoblast secretion of sEndoglin, and this was
unaffected by the presence of HCQ (Figure 3D).

Figure 3: Effect of HCQ on aPL modulation of trophoblast angiogenic factor production. HTR8 cells were
incubated with either no treatment (NT) or the anti-β2GPI mAbs ID2 or IIC5 (20µg/ml) in the presence of
media or HCQ (1µg/ml) for 72hrs. Supernatants were assayed for (A) VEGF, (B) PlGF, (C) sFlt-1, and (D)
sEndoglin. Data are from nine independent experiments. *p<0.05; **p<0.001 relative to NT unless
otherwise indicated.

HCQ limits aPL-induced inhibition of trophoblast IL-6 secretion and cell migration
We previously demonstrated that first trimester trophoblast cell production of IL-6 plays
a role in driving the cell’s spontaneous migration through activation of STAT3, and that
treatment of first trimester trophoblast cells with aPL decreases constitutive IL-6
secretion and cell migration (24). Treatment of trophoblast cells with ID2 or IIC5 reduced

	
  

25

IL-6 secretion, although not to the level of significance. However, IL-6 secretion in the
ID2 or IIC5 treatment groups was significantly increased in the presence of HCQ when
compared to ID2 or IIC5 treatment in the absence of HCQ (Figure 4A). HCQ had no
significant effect on basal trophoblast IL-6 secretion, although there was an increase
noted. Treatment of trophoblast cells with ID2 or IIC5 significantly reduced trophoblast
migration by 65.9±32.0% and 65.6±18.2%, respectively, when compared to the NT
control. The presence of HCQ had no effect on basal trophoblast migration. However,
HCQ significantly reversed ID2 and IIC5-inhibition of trophoblast migration, although
migration did not return to the level of pretreatment controls (Figure 4B).

Figure 4: Effect of HCQ on aPL-induced inhibition of trophoblast IL-6 secretion and migration. HTR8
cells were incubated with either NT or the anti-β2GPI mAbs, ID2 or IIC5 (20µg/ml) in the presence of
media or HCQ (1µg/ml). (A) After 72hrs supernatants were assayed for IL-6. Data are from five
independent experiments. *p<0.05 relative to the NT control unless otherwise indicated. (B) After 48hrs,
cell migration was measured. Data are from four independent experiments. *p<0.05; **p<0.001 relative to
the NT control unless otherwise indicated.

aPL increase secretion of TIMPs and this is partially reversed by HCQ
Trophoblast migration and invasion have been shown to be partially governed by the
balance between trophoblast production of the matrix metalloproteinases (MMPs),
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MMP2 and MMP9, and the tissue inhibitors of matrix metalloproteinases (TIMPs),
TIMP1 and TIMP2 (80). While treatment of trophoblast cells with aPL had no effect on
the expression levels of MMP2 or MMP9 (data not shown), treatment with ID2 or IIC5
significantly increased secretion of TIMP1 and TIMP2 when compared to the NT and
IgG controls (Figure 5A). Furthermore, treatment of trophoblast cells with recombinant
(r) TIMP2 significantly reduced trophoblast migration when compared to the NT control
(Figure 5B). rTIMP2 in combination with rTIMP1 significantly reduced trophoblast
migration when compared to both the NT control and rTIMP1 alone (Figure 5B). As
shown in Figure 6, treatment of trophoblast cells with either ID2 or IIC5 significantly
increased the secretion of (A) TIMP1 and (B) TIMP2, when compared NT control. The
presence of HCQ significantly inhibited ID2-induced secretion of TIMP1 (Figure 6A).
The presence of HCQ significantly increased IIC5-induced TIMP2 secretion (Figure 6B).

Figure 5: aPL upregulate TIMP1 and TIMP2 secretion, which reduces trophoblast migration. (A) HTR8
cells were incubated with no treatment (NT), the anti-β2GPI mAb ID2 or IIC5 (20µg/ml), or an IgG control
(20µg/ml) for 72hrs, after which supernatants were assayed for TIMP1 and TIMP2. Data are from four
independent experiments; **p<0.001 relative to the NT control. (B) HTR8 cells were incubated with either
NT, recombinant TIMP1 (rTIMP1) at 1ng/ml, recombinant TIMP2 (rTIMP2) at 1ng/ml, or rTIMP1 and
rTIMP2 at 1ng/ml for 48hrs after which cell migration was measured. Data are from five independent
experiments. *p<0.05; **p<0.001 relative to NT control unless otherwise indicated.
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Figure 6: Effect of HCQ on aPL-induced trophoblast TIMP1 and TIMP2 secretion. HTR8 cells were
incubated with either no treatment (NT) or the anti-β2GPI mAb ID2 or IIC5 (20µg/ml), in the presence of
media or HCQ (1µg/ml) for 72hrs. Supernatants were assayed for (A) TIMP1 (n=9) and (B) TIMP2 (n=6).
*p<0.05; **p<0.001 relative to the NT control unless otherwise indicated.

DISCUSSION

We hypothesized that HCQ would prevent the aPL-triggered release of pro-inflammatory
cytokines, modulation of angiogenic factors, and inhibition of cell migration. We
specifically hypothesized that HCQ would protect cell migration by preventing aPLinduced inhibition of pro-migratory factor IL-6 and pro-migratory MMPs, as well as
preventing aPL-induced upregulation of anti-migratory TIMPs. Our data show that HCQ
did not prevent the TLR4-mediated pro-inflammatory cytokine response triggered by
aPL. HCQ was also unable to prevent the aPL-induced modulation of pro- and antiangiogenic factor secretion. However, HCQ was able to prevent the aPL-induced
inhibition of IL-6 production and cell migration. The presence of aPL had no effect on
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the expression of MMPs, but increased the expression of both TIMP1 and TIMP2. HCQ
inhibited the aPL-induced secretion of TIMP1, but not TIMP2.

Women with APS continue to face substantial risk for complications during pregnancy,
even when treated with the standard of care, heparin and/or aspirin. Furthermore, several
studies have disputed the effects of heparin on aPL-induced abnormal trophoblast cell
function and have called its efficacy into question (5-10, 81). Thus, further research into
the potential management of APS-related pregnancy complications is critical. While the
drug hydroxychloroquine has been used to treat APS and related autoimmune disorders,
such as lupus, for decades, little is known about its effects on pregnancy outcome in
patients with aPL (55, 56). Therefore, using an in vitro system, we sought to determine
the ability of HCQ to alter aPL-mediated modulation of first trimester trophoblast
function, specifically, cell migration and the secretion of inflammatory cytokines and
angiogenic factors. In this study, we report that HCQ was able to partially limit aPLinduced inhibition of trophoblast migration, possibly through the modulation of IL-6
production.

APS increases the risk of many serious adverse pregnancy outcomes, including recurrent
pregnancy loss and late gestational complications of preeclampsia, HELLP syndrome,
premature delivery, and intrauterine growth restriction. Historically, APS was thought to
cause pregnancy complications through prothrombotic events within the placenta (16).
However, during the last decade, obstetric APS has been recognized as a distinct clinical
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entity from vascular APS, given that patients with APS can display vascular thrombosis
but no obstetric complications, or vice-versa (13).

Recent clinical and experimental studies suggest that the primary causes for adverse
pregnancy events are inflammatory processes, namely cytokine production, complement
deposition, and immune cell activation (18, 20, 21). Studies also indicate that placental
dysfunction and insufficient placentation play a major role in APS-complicated
pregnancies (17, 23, 24). This insufficient placentation is related in part to impaired
migration of trophoblast cells and trophoblast invasion, as well as limited uterine spiral
artery transformation (17, 23, 24). Because aPL are found in maternal circulation as early
as the first trimester, and early impairment of placentation is likely a factor in the
pathology of the obstetric complications of APS, we chose to conduct our investigation
with an in vitro model using human first trimester trophoblast cells (13).

Recent studies have shown that the immunomodulatory properties of HCQ may be
explained by an inhibition of TLR signaling, possibly through interference with
downstream mitogen-activated protein kinase (MAPK) activation and by dampening the
expression of TLRs and their associated signaling molecules (56, 58, 59, 82). HCQ has
been suggested to inhibit the functioning of endosome-bound TLRs that degrade nucleic
acids and are implicated in autoimmune diseases such as APS and lupus (59). Additional
recent evidence suggests that the fusion and differentiation of trophoblast cells are
blocked by aPL via a TLR4 pathway, and that HCQ is able to reverse this effect (40).
Based on this, we postulated that HCQ might prevent the TLR4-dependent trophoblast
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inflammatory cytokine response induced by aPL (20). Moreover, recent studies have
demonstrated that HCQ is able to reduce the binding of aPL-β2GPI complexes to
phospholipid bilayers and protect the anticoagulant protein annexin A5 from disruption
by aPL in term trophoblast cells (72-74). In our initial experiments, we found that high
doses of HCQ (10µg/ml and 100µg/ml) negatively affected cell viability. Therefore, a
dose of 1µg/ml was selected for use in further experiments, which correlated with
concentrations previously used (72-74).

We found that HCQ alone had no significant effect on basal trophoblast secretion of
inflammatory cytokines or angiogenic factors. Moreover, HCQ had no effect on aPLinduced IL-8 and IL-1β production, suggesting that the ability of HCQ to inhibit TLR4
signaling may not be applicable to the trophoblast (82). Alternatively, it could be a
reflection of the short period of exposure of the trophoblast to HCQ. While an in vitro
exposure to HCQ can inhibit activation of the endosomal TLRs (58), the ability of HCQ
to down-modulate the TLR4 signaling pathway has only been shown in vivo after a long
term exposure of 6 months (82). Our data also suggest that HCQ does not prevent antiβ2GPI mAbs binding to first trimester trophoblast cells. This is in contrast to what has
been reported for the effects of HCQ on aPL-β2GPI complexes binding to lipid bilayers
and for aPL binding to term trophoblast, even though for these studies as well as our own,
aPL and HCQ were delivered to the cells at the same time (72-74). While HCQ had no
effect on aPL-induced PlGF or sEndoglin secretion, we did observe a slight, but
significant, reduction in VEGF secretion induced by one of the anti-β2GPI mAbs, ID2.
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This is in keeping with a study showing that that chloroquine reduces epidermal VEGF
expression (83).

While HCQ did not have an overt effect on the angiogenic factor profile, nor did it
prevent aPL-induced trophoblast inflammation, we did observe an effect on the aPLmediated reduction in IL-6 secretion and cell migration. Conflicting reports of the effects
of HCQ on cell migration exist, but its effects on migration in the trophoblast have not
been extensively studied (84, 85). It has previously been reported that treatment of
trophoblast cells with aPL reduced basal IL-6 secretion, STAT3 phosphorylation, and
trophoblast migration (24). Moreover, trophoblast migration has been shown to be
inhibited by blocking the IL-6-to-IL-6 receptor interaction, suggesting this to be the
mechanism by which aPL limit cell migration (24). In this current study, HCQ was able
to reverse the effect of aPL on IL-6 production. However, the aPL-induced reduction in
cell migration was only partially reversed by the presence of HCQ. This finding suggests
that while HCQ might have a beneficial effect on aPL-induced inhibition of trophoblast
migration, another factor in addition to IL-6 may be involved in its regulation, and this
factor is not altered by HCQ.

Trophoblast migration and invasion can be regulated by the balance between the cell’s
production of the matrix metalloproteinases, MMP2 and MMP9, and the tissue inhibitors
of matrix metalloproteinases, TIMP1 and TIMP2 (80). Therefore, we sought to determine
whether aPL disrupted this balance of MMPs and TIMPs in the trophoblast, and whether
the presence of HCQ provided any protection. Unlike previous reports that have shown
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aPL to reduce MMP2 and MMP9 expression in trophoblast cells, we found MMP2 and
MMP9 expression to be unchanged after exposure to either of the anti-β2GPI mAbs (43,
47, 48).

Instead, our data show for the first time that aPL upregulate both TIMP1 and TIMP2
secretion, and that the presence of recombinant TIMP2 either alone, or in combination
with TIMP1, can limit trophoblast migration, similarly to treatment with aPL or
disruption of IL-6 signaling (24). However, the presence of HCQ was not able to entirely
prevent ID2-induced TIMP1 secretion and had no protective effect on aPL-induced
TIMP2 secretion. Our findings are supported by previous data that chloroquine promotes
endothelial cell migration (84), and are inconsistent with previous reports that
chloroquine increases TIMP1 in serum levels of patients with lupus (85). Our studies
indicate that the beneficial effects of HCQ on IL-6 and TIMP1 secretion, but its inability
to affect TIMP2 secretion, may explain why HCQ was able to improve but not wholly
reverse the inhibition of trophoblast migration by aPL. These data are mirrored by a
recent study examining the effects of an anti-inflammatory product of aspirin, aspirintriggered lipoxin (ATL), on HTR8 cell function (50). This study found that ATL was able
to reverse both the aPL-induced downregulation of IL-6 and the inhibition of cell
migration, reinforcing the importance of IL-6 levels in migration of trophoblast cells,
previously shown to be related to the STAT3 pathway (24). This study also found that
aPL induced an upregulation of TIMP2, supporting our data. The upregulation of TIMP2
was not reversed by ATL. This evidence, in combination with our study, could suggest
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that there are multiple mechanisms by which aPL inhibit trophoblast migration, and that
drugs such as HCQ and ATL target some but not all of these pathways.

In summary, our research demonstrates that HCQ was able to partially but significantly
reverse the aPL-induced inhibition of trophoblast migration. Our research showed that
HCQ was able to reverse the aPL-induced down-regulation of promigratory cytokine IL6, and was able to partially reverse the aPL-induced upregulation of TIMP1. However,
HCQ was found to have no effect on aPL-induced upregulation of pro-inflammatory
cytokines or aPL-induced modulation of angiogenic factors. Our study did not reveal any
overt negative effects of HCQ on basal trophoblast function. Together, our data indicate
that HCQ may be useful as a therapeutic agent to target pregnancy complications in
women with APS. Moreover, the potential benefit of HCQ on trophoblast migration, but
not on the inflammatory or angiogenic profile, suggests that a combination therapy that
includes HCQ may offer greater protection to women with APS during pregnancy.

It is important to note that these in vitro studies may not perform as a comprehensive
model of the in vivo condition of APS during pregnancy. Our results show that HCQ has
no negative effect on basal trophoblast function, and there is a broad fund of research
demonstrating the safety of HCQ in pregnancy, as it is often used to treat APS and lupus
as an anti-inflammatory and immunomodulatory drug. Therefore, it may be useful to
examine whether HCQ can produce any benefits during pregnancy in the APS population
as a clinical trial. In cases with APS patients at high risk for obstetrical complications, it
could also be argued that HCQ may be a safe and viable option for treatment. However,
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further experimentation is necessary to determine the optimal combination of drug
therapy in this complex condition.

	
  

35

REFERENCES
1.

George, D., and Erkan, D. 2009. Antiphospholipid syndrome. Prog Cardiovasc
Dis 52:115-125.

2.

Funai, E.F., Friedlander, Y., Paltiel, O., Tiram, E., Xue, X., Deutsch, L., and
Harlap, S. 2005. Long-term mortality after preeclampsia. Epidemiology 16:206215.

3.

Abisror, N., Mekinian, A., Lachassinne, E., Nicaise-Roland, P., De Pontual, L.,
Chollet-Martin, S., Boddaert, N., Carbillon, L., and Fain, O. 2013. Autism
spectrum disorders in babies born to mothers with antiphospholipid syndrome.
Semin Arthritis Rheum 43:348-351.

4.

Nacinovich, R., Galli, J., Bomba, M., Filippini, E., Parrinello, G., Nuzzo, M.,
Lojacono, A., Motta, M., and Tincani, A. 2008. Neuropsychological development
of children born to patients with antiphospholipid syndrome. Arthritis Rheum
59:345-351.

5.

Branch, D.W., and Khamashta, M.A. 2003. Antiphospholipid syndrome: obstetric
diagnosis, management, and controversies. Obstet Gynecol 101:1333-1344.

6.

Backos, M., Rai, R., Baxter, N., Chilcott, I.T., Cohen, H., and Regan, L. 1999.
Pregnancy complications in women with recurrent miscarriage associated with
antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet
Gynaecol 106:102-107.

7.

Cohn, D.M., Goddijn, M., Middeldorp, S., Korevaar, J.C., Dawood, F., and
Farquharson, R.G. 2010. Recurrent miscarriage and antiphospholipid antibodies:
prognosis of subsequent pregnancy. J Thromb Haemost 8:2208-2213.

8.

Farquharson, R.G., Quenby, S., and Greaves, M. 2002. Antiphospholipid
syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet
Gynecol 100:408-413.

9.

Han, C.S., Mulla, M.J., Brosens, J.J., Chamley, L.W., Paidas, M.J., Lockwood,
C.J., and Abrahams, V.M. 2011. Aspirin and heparin effect on basal and
antiphospholipid antibody modulation of trophoblast function. Obstet Gynecol
118:1021-1028.

	
  
10.

36
Stephenson, M.D., Ballem, P.J., Tsang, P., Purkiss, S., Ensworth, S., Houlihan,
E., and Ensom, M.H. 2004. Treatment of antiphospholipid antibody syndrome
(APS) in pregnancy: a randomized pilot trial comparing low molecular weight
heparin to unfractionated heparin. J Obstet Gynaecol Can 26:729-734.

11.

Ruiz-Irastorza, G., Crowther, M., Branch, W., and Khamashta, M.A. 2010.
Antiphospholipid syndrome. Lancet 376:1498-1509.

12.

Gomez-Puerta, J.A., and Cervera, R. 2014. Diagnosis and classification of the
antiphospholipid syndrome. J Autoimmun 48-49:20-25.

13.

D'Ippolito, S., Meroni, P.L., Koike, T., Veglia, M., Scambia, G., and Di Simone,
N. 2014. Obstetric antiphospholipid syndrome: a recent classification for an old
defined disorder. Autoimmun Rev 13:901-908.

14.

Comarmond, C., and Cacoub, P. 2013. Antiphospholipid syndrome: from
pathogenesis to novel immunomodulatory therapies. Autoimmun Rev 12:752-757.

15.

Kutteh, W.H., and Hinote, C.D. 2014. Antiphospholipid antibody syndrome.
Obstet Gynecol Clin North Am 41:113-132.

16.

de Jesus, G.R., Agmon-Levin, N., Andrade, C.A., Andreoli, L., Chighizola, C.B.,
Porter, T.F., Salmon, J., Silver, R.M., Tincani, A., and Branch, D.W. 2014. 14th
International Congress on Antiphospholipid Antibodies Task Force report on
obstetric antiphospholipid syndrome. Autoimmun Rev 13:795-813.

17.

Sebire, N.J., Fox, H., Backos, M., Rai, R., Paterson, C., and Regan, L. 2002.
Defective endovascular trophoblast invasion in primary antiphospholipid antibody
syndrome-associated early pregnancy failure. Hum Reprod 17:1067-1071.

18.

Berman, J., Girardi, G., and Salmon, J.E. 2005. TNF-alpha is a critical effector
and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J
Immunol 174:485-490.

19.

Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J.M., Kraus, D.,
Hollmann, T.J., Casali, P., Caroll, M.C., Wetsel, R.A., et al. 2003. Complement
C5a receptors and neutrophils mediate fetal injury in the antiphospholipid
syndrome. J Clin Invest 112:1644-1654.

20.

Mulla, M.J., Brosens, J.J., Chamley, L.W., Giles, I., Pericleous, C., Rahman, A.,
Joyce, S.K., Panda, B., Paidas, M.J., and Abrahams, V.M. 2009. Antiphospholipid

	
  

37
antibodies induce a pro-inflammatory response in first trimester trophoblast via
the TLR4/MyD88 pathway. Am J Reprod Immunol 62:96-111.

21.

Redecha, P., Tilley, R., Tencati, M., Salmon, J.E., Kirchhofer, D., Mackman, N.,
and Girardi, G. 2007. Tissue factor: a link between C5a and neutrophil activation
in antiphospholipid antibody induced fetal injury. Blood 110:2423-2431.

22.

Van Horn, J.T., Craven, C., Ward, K., Branch, D.W., and Silver, R.M. 2004.
Histologic features of placentas and abortion specimens from women with
antiphospholipid and antiphospholipid-like syndromes. Placenta 25:642-648.

23.

Bose, P., Kadyrov, M., Goldin, R., Hahn, S., Backos, M., Regan, L., and
Huppertz, B. 2006. Aberrations of early trophoblast differentiation predispose to
pregnancy failure: lessons from the anti-phospholipid syndrome. Placenta
27:869-875.

24.

Mulla, M.J., Myrtolli, K., Brosens, J.J., Chamley, L.W., Kwak-Kim, J.Y., Paidas,
M.J., and Abrahams, V.M. 2010. Antiphospholipid antibodies limit trophoblast
migration by reducing IL-6 production and STAT3 activity. Am J Reprod
Immunol 63:339-348.

25.

Chamley, L.W., Allen, J.L., and Johnson, P.M. 1997. Synthesis of beta2
glycoprotein 1 by the human placenta. Placenta 18:403-410.

26.

La Rosa, L., Meroni, P.L., Tincani, A., Balestrieri, G., Faden, D., Lojacono, A.,
Morassi, L., Brocchi, E., Del Papa, N., Gharavi, A., et al. 1994. Beta 2
glycoprotein I and placental anticoagulant protein I in placentae from patients
with antiphospholipid syndrome. J Rheumatol 21:1684-1693.

27.

Valesini, G., and Alessandri, C. 2005. New facet of antiphospholipid antibodies.
Ann N Y Acad Sci 1051:487-497.

28.

Abrahams, V.M. 2009. Mechanisms of antiphospholipid antibody-associated
pregnancy complications. Thromb Res 124:521-525.

29.

Norwitz, E.R., Schust, D.J., and Fisher, S.J. 2001. Implantation and the survival
of early pregnancy. N Engl J Med 345:1400-1408.

30.

Dubinsky, V., Poehlmann, T.G., Suman, P., Gentile, T., Markert, U.R., and
Gutierrez, G. 2010. Role of regulatory and angiogenic cytokines in invasion of
trophoblastic cells. Am J Reprod Immunol 63:193-199.

	
  
31.

38
Fitzgerald, J.S., Poehlmann, T.G., Schleussner, E., and Markert, U.R. 2008.
Trophoblast invasion: the role of intracellular cytokine signalling via signal
transducer and activator of transcription 3 (STAT3). Hum Reprod Update 14:335344.

32.

Suman, P., Poehlmann, T.G., Prakash, G.J., Markert, U.R., and Gupta, S.K. 2009.
Interleukin-11 increases invasiveness of JEG-3 choriocarcinoma cells by
modulating STAT3 expression. J Reprod Immunol 82:1-11.

33.

Zhu, J., Zhong, M., Pang, Z., and Yu, Y. 2014. Dysregulated expression of matrix
metalloproteinases and their inhibitors may participate in the pathogenesis of preeclampsia and fetal growth restriction. Early Hum Dev 90:657-664.

34.

Palei, A.C., Sandrim, V.C., Cavalli, R.C., and Tanus-Santos, J.E. 2008.
Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and
their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in
preeclampsia and gestational hypertension. Clin Biochem 41:875-880.

35.

Xu, P., Wang, Y.L., Zhu, S.J., Luo, S.Y., Piao, Y.S., and Zhuang, L.Z. 2000.
Expression of matrix metalloproteinase-2, -9, and -14, tissue inhibitors of
metalloproteinase-1, and matrix proteins in human placenta during the first
trimester. Biol Reprod 62:988-994.

36.

Jauniaux, E., and Burton, G.J. 2005. Pathophysiology of histological changes in
early pregnancy loss. Placenta 26:114-123.

37.

Di Simone, N., Castellani, R., Caliandro, D., and Caruso, A. 2001. Monoclonal
anti-annexin V antibody inhibits trophoblast gonadotropin secretion and induces
syncytiotrophoblast apoptosis. Biol Reprod 65:1766-1770.

38.

Di Simone, N., Caliandro, D., Castellani, R., Ferrazzani, S., and Caruso, A. 2000.
Interleukin-3 and human trophoblast: in vitro explanations for the effect of
interleukin in patients with antiphospholipid antibody syndrome. Fertil Steril
73:1194-1200.

39.

Quenby, S., Mountfield, S., Cartwright, J.E., Whitley, G.S., Chamley, L., and
Vince, G. 2005. Antiphospholipid antibodies prevent extravillous trophoblast
differentiation. Fertil Steril 83:691-698.

	
  
40.

39
Marchetti, T., Ruffatti, A., Wuillemin, C., de Moerloose, P., and Cohen, M. 2014.
Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid
antibodies. J Thromb Haemost 12:910-920.

41.

Gleicher, N., Harlow, L., and Zilberstein, M. 1992. Regulatory effect of
antiphospholipid antibodies on signal transduction: a possible model for
autoantibody-induced reproductive failure. Am J Obstet Gynecol 167:637-642.

42.

Di Simone, N., Raschi, E., Testoni, C., Castellani, R., D'Asta, M., Shi, T., Krilis,
S.A., Caruso, A., and Meroni, P.L. 2005. Pathogenic role of anti-beta 2glycoprotein I antibodies in antiphospholipid associated fetal loss:
characterisation of beta 2-glycoprotein I binding to trophoblast cells and
functional effects of anti-beta 2-glycoprotein I antibodies in vitro. Ann Rheum Dis
64:462-467.

43.

Di Simone, N., Marana, R., Castellani, R., Di Nicuolo, F., D'Alessio, M.C.,
Raschi, E., Borghi, M.O., Chen, P.P., Sanguinetti, M., Caruso, A., et al. 2010.
Decreased expression of heparin-binding epidermal growth factor-like growth
factor as a newly identified pathogenic mechanism of antiphospholipid-mediated
defective placentation. Arthritis Rheum 62:1504-1512.

44.

Peaceman, A.M., and Rehnberg, K.A. 1993. The effect of immunoglobulin G
fractions from patients with lupus anticoagulant on placental prostacyclin and
thromboxane production. Am J Obstet Gynecol 169:1403-1406.

45.

Rand, J.H., Wu, X.X., Guller, S., Scher, J., Andree, H.A., and Lockwood, C.J.
1997. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on
syncytiotrophoblast apical membranes and in culture media of placental villi. Am
J Obstet Gynecol 177:918-923.

46.

Carroll, T.Y., Mulla, M.J., Han, C.S., Brosens, J.J., Chamley, L.W., Giles, I.,
Pericleous, C., Rahman, A., Sfakianaki, A.K., Paidas, M.J., et al. 2011.
Modulation of trophoblast angiogenic factor secretion by antiphospholipid
antibodies is not reversed by heparin. Am J Reprod Immunol 66:286-296.

47.

Kovacevic, T.M., Radojcic, L., Tosic, N.M., Pavlovic, S.T., and Vicovac, L.M.
2013. Monoclonal antibody 26 cross-reactive with beta2-glycoprotein I affects

	
  

40
human trophoblast invasion in vitro. Eur J Obstet Gynecol Reprod Biol 171:2329.

48.

Blank, M., Anafi, L., Zandman-Goddard, G., Krause, I., Goldman, S., Shalev, E.,
Cervera, R., Font, J., Fridkin, M., Thiesen, H.J., et al. 2007. The efficacy of
specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS):
trophoblast invasiveness and APS animal model. Int Immunol 19:857-865.

49.

Odiari, E.A., Mulla, M.J., Sfakianaki, A.K., Paidas, M.J., Stanwood, N.L.,
Gariepy, A., Brosens, J.J., Chamley, L.W., and Abrahams, V.M. 2012. Pravastatin
does not prevent antiphospholipid antibody-mediated changes in human first
trimester trophoblast function. Hum Reprod 27:2933-2940.

50.

Alvarez, A.M., Mulla, M.J., Chamley, L.W., Cadavid, A.P., and Abrahams, V.M.
2014. Aspirin-triggered lipoxin prevents antiphospholipid antibody effects on
human trophoblast migration and endothelial interactions. Arthritis Rheumatol.

51.

D'Ippolito, S., Marana, R., Di Nicuolo, F., Castellani, R., Veglia, M., Stinson, J.,
Scambia, G., and Di Simone, N. 2012. Effect of Low Molecular Weight Heparins
(LMWHs) on antiphospholipid Antibodies (aPL)-mediated inhibition of
endometrial angiogenesis. PLoS One 7:e29660.

52.

Gu, Y., Lewis, D.F., and Wang, Y. 2008. Placental productions and expressions
of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental
growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab
93:260-266.

53.

Lam, C., Lim, K.H., and Karumanchi, S.A. 2005. Circulating angiogenic factors
in the pathogenesis and prediction of preeclampsia. Hypertension 46:1077-1085.

54.

Maynard, S.E., Min, J.Y., Merchan, J., Lim, K.H., Li, J., Mondal, S., Libermann,
T.A., Morgan, J.P., Sellke, F.W., Stillman, I.E., et al. 2003. Excess placental
soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial
dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649658.

55.

Erkan, D., and Lockshin, M.D. 2006. Antiphospholipid syndrome. Curr Opin
Rheumatol 18:242-248.

	
  
56.

41
Kyburz, D., Brentano, F., and Gay, S. 2006. Mode of action of
hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor
signaling. Nat Clin Pract Rheumatol 2:458-459.

57.

Ben-Zvi, I., Kivity, S., Langevitz, P., and Shoenfeld, Y. 2012.
Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol
42:145-153.

58.

Kuznik, A., Bencina, M., Svajger, U., Jeras, M., Rozman, B., and Jerala, R. 2011.
Mechanism of endosomal TLR inhibition by antimalarial drugs and
imidazoquinolines. J Immunol 186:4794-4804.

59.

Lafyatis, R., York, M., and Marshak-Rothstein, A. 2006. Antimalarial agents:
closing the gate on Toll-like receptors? Arthritis Rheum 54:3068-3070.

60.

Ziegler, H.K., and Unanue, E.R. 1982. Decrease in macrophage antigen
catabolism caused by ammonia and chloroquine is associated with inhibition of
antigen presentation to T cells. Proc Natl Acad Sci U S A 79:175-178.

61.

Tishler, M., Yaron, I., Shirazi, I., and Yaron, M. 1999. Hydroxychloroquine
treatment for primary Sjogren's syndrome: its effect on salivary and serum
inflammatory markers. Ann Rheum Dis 58:253-256.

62.

Costedoat-Chalumeau, N., Dunogue, B., Morel, N., Le Guern, V., and GuettrotImbert, G. 2014. Hydroxychloroquine: a multifaceted treatment in lupus. Presse
Med 43:e167-180.

63.

Takeda, K., and Akira, S. 2007. Toll-like receptors. Curr Protoc Immunol Chapter
14:Unit 14 12.

64.

Weber, S.M., Chen, J.M., and Levitz, S.M. 2002. Inhibition of mitogen-activated
protein kinase signaling by chloroquine. J Immunol 168:5303-5309.

65.

Taylor, W.R., and White, N.J. 2004. Antimalarial drug toxicity: a review. Drug
Saf 27:25-61.

66.

Tehrani, R., Ostrowski, R.A., Hariman, R., and Jay, W.M. 2008. Ocular toxicity
of hydroxychloroquine. Semin Ophthalmol 23:201-209.

67.

Clowse, M.E., Magder, L., Witter, F., and Petri, M. 2006. Hydroxychloroquine in
lupus pregnancy. Arthritis Rheum 54:3640-3647.

	
  
68.

42
Scoble, T., Wijetilleka, S., and Khamashta, M.A. 2011. Management of refractory
anti-phospholipid syndrome. Autoimmun Rev 10:669-673.

69.

Levy, M., Buskila, D., Gladman, D.D., Urowitz, M.B., and Koren, G. 1991.
Pregnancy outcome following first trimester exposure to chloroquine. Am J
Perinatol 8:174-178.

70.

Costedoat-Chalumeau, N., Amoura, Z., Duhaut, P., Huong, D.L., Sebbough, D.,
Wechsler, B., Vauthier, D., Denjoy, I., Lupoglazoff, J.M., and Piette, J.C. 2003.
Safety of hydroxychloroquine in pregnant patients with connective tissue
diseases: a study of one hundred thirty-three cases compared with a control group.
Arthritis Rheum 48:3207-3211.

71.

Osadchy, A., Ratnapalan, T., and Koren, G. 2011. Ocular toxicity in children
exposed in utero to antimalarial drugs: review of the literature. J Rheumatol
38:2504-2508.

72.

Rand, J.H., Wu, X.X., Quinn, A.S., Chen, P.P., Hathcock, J.J., and Taatjes, D.J.
2008. Hydroxychloroquine directly reduces the binding of antiphospholipid
antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood
112:1687-1695.

73.

Rand, J.H., Wu, X.X., Quinn, A.S., and Taatjes, D.J. 2010. The annexin A5mediated pathogenic mechanism in the antiphospholipid syndrome: role in
pregnancy losses and thrombosis. Lupus 19:460-469.

74.

Wu, X.X., Guller, S., and Rand, J.H. 2011. Hydroxychloroquine reduces binding
of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5
expression. Am J Obstet Gynecol 205:576 e577-514.

75.

Graham, C.H., Hawley, T.S., Hawley, R.G., MacDougall, J.R., Kerbel, R.S.,
Khoo, N., and Lala, P.K. 1993. Establishment and characterization of first
trimester human trophoblast cells with extended lifespan. Exp Cell Res 206:204211.

76.

Irving, J.A., Lysiak, J.J., Graham, C.H., Hearn, S., Han, V.K., and Lala, P.K.
1995. Characteristics of trophoblast cells migrating from first trimester chorionic
villus explants and propagated in culture. Placenta 16:413-433.

	
  
77.

43
Chamley, L.W., Konarkowska, B., Duncalf, A.M., Mitchell, M.D., and Johnson,
P.M. 2001. Is interleukin-3 important in antiphospholipid antibody-mediated
pregnancy failure? Fertil Steril 76:700-706.

78.

Chamley, L.W., Duncalf, A.M., Konarkowska, B., Mitchell, M.D., and Johnson,
P.M. 1999. Conformationally altered beta 2-glycoprotein I is the antigen for anticardiolipin autoantibodies. Clin Exp Immunol 115:571-576.

79.

Abrahams, V.M., Aldo, P.B., Murphy, S.P., Visintin, I., Koga, K., Wilson, G.,
Romero, R., Sharma, S., and Mor, G. 2008. TLR6 modulates first trimester
trophoblast responses to peptidoglycan. J Immunol 180:6035-6043.

80.

Huppertz, B., Kertschanska, S., Demir, A.Y., Frank, H.G., and Kaufmann, P.
1998. Immunohistochemistry of matrix metalloproteinases (MMP), their
substrates, and their inhibitors (TIMP) during trophoblast invasion in the human
placenta. Cell Tissue Res 291:133-148.

81.

Erkan, D., Yazici, Y., Peterson, M.G., Sammaritano, L., and Lockshin, M.D.
2002. A cross-sectional study of clinical thrombotic risk factors and preventive
treatments in antiphospholipid syndrome. Rheumatology (Oxford) 41:924-929.

82.

Piconi, S., Parisotto, S., Rizzardini, G., Passerini, S., Terzi, R., Argenteri, B.,
Meraviglia, P., Capetti, A., Biasin, M., Trabattoni, D., et al. 2011.
Hydroxychloroquine drastically reduces immune activation in HIV-infected,
antiretroviral therapy-treated immunologic nonresponders. Blood 118:3263-3272.

83.

Lesiak, A., Narbutt, J., Kobos, J., Kordek, R., Sysa-Jedrzejowska, A., Norval, M.,
and Wozniacka, A. 2009. Systematic administration of chloroquine in discoid
lupus erythematosus reduces skin lesions via inhibition of angiogenesis. Clin Exp
Dermatol 34:570-575.

84.

Inyang, A.L., Bikfalvi, A., Lu, H., and Tobelem, G. 1990. Chloroquine's
modulation of endothelial cell activity induced with basic fibroblast growth factor
and human serum: effect on mitogenesis, protease production and cell migration.
Cell Biol Int Rep 14:35-46.

85.

Lesiak, A., Narbutt, J., Sysa-Jedrzejowska, A., Lukamowicz, J., McCauliffe, D.P.,
and Wozniacka, A. 2010. Effect of chloroquine phosphate treatment on serum

	
  

44
MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus
19:683-688.

